DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06916091

CompletedPhase 1

A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight

A Phase 1, Investigator- and Participant-Blinded, Placebo Controlled, Randomized, Single Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight

Asset

Eloralintide

Subcutaneous · Amylin analog

Listed sites

1

Recruiting sites

—

Enrollment

30

actual

Study population

Obesity / overweight

Key I/E criterion

•BMI 27-40

Primary endpoint

•Treatment-emergent AEs (any) (Treatment-emergent AEs (any), Serious AEs (any))

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06916091
Org study ID27320
Secondary IDJ3R-MC-YDADEli Lilly and Company

Timeline

Milestones

Study first posted2025-04-08actual
Study start2025-04-21actual
Primary completion2025-09-09actual
Study completion2025-09-09actual
Last update posted2025-11-19actual

Assets

Investigational agents

Eloralintide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age21 Years
Maximum age65 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Chinese participants. To qualify as Chinese, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China
•Have had a stable body weight for 3 months prior to screening. Participants with body weight change of less than 5% will be allowed
•Have not modified diet or adopted any nutritional lifestyle modification for 3 months before randomization
•Have clinical laboratory test results within a normal range for the population or investigative site at screening and lead-in, or results with acceptable deviations that are judged to be not clinically significant by the investigator
•Have a body mass index (BMI) within the range 27 to 40 kilogram per square meter (kg/m²)

Exclusion criteria

•Are pregnant, or intend to become pregnant or to breastfeed during the study
•Have known allergies to related compounds of eloralintide
•Have any of the following abnormal blood pressure (BP) and/or pulse rate at screening, constituting a risk when taking the investigational product with minor deviations judged to be acceptable by the investigator:
–Supine BP > 160/90 millimeter mercury (mmHg)
–Supine pulse rate < 50 or > 100 beats per minute (bpm)
–Orthostatic hypotension
•Have significant previous or current history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drugs
•Regularly use known drugs of abuse and/or show positive findings on drug screening that are not consistent with the medical history or concomitant medication history
•Have donated blood of more than 450 mL within the previous 3 months of study screening, or intend to donate blood during the course of the study
•Have a history of chronic medical conditions involving the heart, liver, or kidneys
•Have a medical history or current evidence of clinically significant cardiac condition

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

3 endpoints
Primary/protocol endpoint

Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Time frame:Baseline to Study Completion (Up to 10 Weeks)

Treatment-emergent AEs (any)

event count, event

componentsTreatment-emergent AEs (any), Serious AEs (any)

Secondary/protocol endpoint

Pharmacokinetics (PK): Maximum Concentration (Cmax) of Eloralintide

Time frame:Baseline to Study Completion (Up to 10 Weeks)

Cmax

concentration, descriptive

Secondary/protocol endpoint

PK: Area Under the Concentration Versus Time Curve (AUC) of Eloralintide

Time frame:Baseline to Study Completion (Up to 10 Weeks)

AUC₀–∞

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.